Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Intercept Pharmaceuticals, acquired by Alfasigma S.p.A. in November 2023, is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for progressive non-viral liver diseases. Their flagship product, Ocaliva (obeticholic acid), is approved for primary biliary cholangitis (PBC). The company has a strong research focus on addressing unmet medical needs in complex liver conditions, now continuing its mission as an integral part of Alfasigma's global operations.
Serves as a significant operational center for Alfasigma's liver disease franchise in the United States, housing administrative, commercial, and R&D support functions related to former Intercept activities.
Modern office space in a multi-tenant building, equipped to support biopharmaceutical operations. Specific architectural highlights are not publicly prominent as it's typically leased and fitted-out commercial space.
A culture historically rooted in scientific innovation and patient-centricity, focused on tackling challenging liver diseases. Post-acquisition, this is integrating with Alfasigma's broader corporate culture and values.
Represents a key hub for Alfasigma's presence in the U.S. liver disease market, leveraging Intercept's established expertise, product portfolio, and research capabilities.
As part of Alfasigma S.p.A., Intercept Pharmaceuticals contributes to a significant global presence, particularly in North America and Europe. Functions supported globally include research and development in liver diseases, clinical trial management, medical affairs, regulatory submissions, and commercial operations for its specialized therapeutics.
305 Madison Avenue
Morristown
NJ
USA
Address: Intercept Pharma Europe Ltd., The Economist Building, 25 St James's Street, London, SW1A 1HG, UK
To lead and coordinate Alfasigma's liver disease therapeutic area activities in Europe and other ex-US international markets, ensuring market access and delivery of therapies to patients.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Intercept Pharmaceuticals' leadership includes:
Intercept Pharmaceuticals has been backed by several prominent investors over the years, including:
Following its acquisition by Alfasigma S.p.A. in November 2023, Intercept Pharmaceuticals' standalone executive team was dissolved. Former CEO Jerome Durso departed, and oversight transitioned to Alfasigma's leadership, including Pier Vincenzo Colli (CEO, Alfasigma S.p.A.) and Bryan J. Smith (President & GM, Alfasigma USA).
Discover the tools Intercept Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Intercept Pharmaceuticals is now part of Alfasigma, historical email formats at Intercept often followed common corporate structures. A widely used pattern is combining the first initial with the last name. For current Alfasigma communications, their specific email format would apply.
[first_initial][last]@interceptpharma.com
Format
jdoe@interceptpharma.com
Example
70%
Success rate
Alfasigma Press Release • June 5, 2024
Alfasigma announced new data presentations for Ocaliva® (obeticholic acid) at The International Liver Congress™ (ILC), EASL Congress 2024, highlighting its ongoing commitment to primary biliary cholangitis (PBC) research and treatment. The data reinforce the long-term efficacy and safety profile of Ocaliva....more
Fierce Pharma • November 8, 2023
Alfasigma S.p.A. finalized its acquisition of Intercept Pharmaceuticals for $1.9 billion ($19.00 per share in cash). This strategic move significantly expands Alfasigma's gastroenterology and hepatology portfolio, notably adding Ocaliva, a treatment for primary biliary cholangitis....more
Endpoints News • June 23, 2023
Intercept Pharmaceuticals received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for obeticholic acid (OCA) for pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). This marked the second FDA rejection for OCA in this indication....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Intercept Pharmaceuticals, are just a search away.